Dizal Pharmaceutical Co., Ltd, a pharmaceutical entity listed in Shanghai (SHA: 688192), has unveiled its financial report for the first half of 2024, showcasing a revenue of RMB 204 million. This substantial growth is attributed to the rapid adoption of sunvozertinib, a cutting-edge epidermal growth factor receptor (EGFR) inhibitor, which received regulatory approval in China in August 2023 for the treatment of EGFR Exon20ins mutated non-small cell lung cancer. The company has reported a marked improvement in its financial health, with a net loss to shareholders of the parent company declining for three consecutive quarters, exhibiting a significant 33% reduction in the first half of 2024 when compared to the corresponding period in the previous year.
In a significant regulatory milestone, golidocitinib was granted marketing approval in China in June, emerging as the pioneering and sole Janus kinase 1 (JAK1) selective inhibitor globally for the treatment of relapsed or refractory (r/r) peripheral T-Cell lymphoma (PTCL) patients.
Furthermore, the company’s robust pipeline is gaining momentum with four additional candidates advancing into global, multi-center clinical trials. Among these is DZD8586, a dual inhibitor of LYN and Bruton’s tyrosine kinase (BTK), which holds promise for the treatment of various malignancies.- Flcube.com
